Trastuzumab

    verified Antineoplastic agent

    Trastuzumab — package

    info General information

    Name Trastuzumab, 440 mg, lyophilisate for concentrate for solution for infusion, supplied with solvent – bacteriostatic water for injections
    INN Trastuzumab
    Active substance Trastuzumab
    Pharmacotherapeutic group Antineoplastic agents. Monoclonal antibodies and antibody-drug conjugates. HER2 (human epidermal growth factor receptor 2) inhibitors. Trastuzumab
    Dosage form Lyophilisate for concentrate for solution for infusion, supplied with solvent – bacteriostatic water for injections.
    Packaging

    440 mg of the product in a vial. 20 mL of solvent (bacteriostatic water for injections) in a vial.

    1 vial with the product (440 mg) and 1 vial with the solvent (bacteriostatic water for injections) are placed in a blister pack. 1 blister pack is placed in a cardboard box.

    Manufacturer Karaganda Pharmaceutical Complex LLP EU GMP

    assignment_turned_in Indications

    Your doctor may prescribe Trastuzumab for the treatment of breast and stomach cancer when:

    • You have early breast cancer with a high level of HER2 protein.
    • You have metastatic breast cancer (breast cancer that has spread beyond the original tumor) with a high level of HER2. Trastuzumab may be prescribed in combination with the chemotherapy medicine paclitaxel or docetaxel as first-line treatment of metastatic breast cancer, or it may be prescribed alone if other treatments have been unsuccessful. It is also used in combination with medicines called aromatase inhibitors in patients with a high level of HER2 and hormone receptor-positive metastatic breast cancer (cancer that is sensitive to the presence of female sex hormones).
    • You have metastatic stomach cancer with a high level of HER2, in combination with other anticancer medicines capecitabine or 5-fluorouracil and cisplatin.